Condition: Small Cell Lung Cancer · Sponsor: Amgen
The primary objective of this trial is to evaluate the safety and tolerability of tarlatamab in combination with ZL-1310 with or without durvalumab and to determine the maximum tolerated combination dose (MTCD) and/or recommended phase 2 dose (RP2D) of ZL-1310 in combination with tarlatamab.
This description comes directly from the study's public registry record.
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
Always discuss trial participation with your own doctor first.
| New York University Cancer Institute | New York, New York, United States | Recruiting |
| Baptist Cancer Center | Memphis, Tennessee, United States | Recruiting |
| Next Virginia | Fairfax, Virginia, United States | Recruiting |
| Adana Sehir Egitim ve Arastirma Hastanesi | Adana, Turkey (Türkiye) | Recruiting |
| Hacettepe Universitesi Tip Fakultesi Hastanesi | Ankara, Turkey (Türkiye) | Recruiting |
| Izmir Ekonomi Universitesi Medical Point Hastanesi | Izmir, Turkey (Türkiye) | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07531095